To characterize HIV-1 genotypes in candidate populations for a prime-boost phase III vaccine trial in Thailand, specimens from prevalent and incident HIV-1 infections from a family planning clinic population in Rayong Province and a community cohort in Chon Buri Province, collected from 1998 to 2001, were genotyped. A new multiregion hybridization assay, MHAbce, capable of distinguishing HIV-1 CRF01_AE, subtype B, and subtype C and their recombinants, was developed and applied to prevalent infections. Most incident and selected prevalent infections were studied by complete genome sequencing. By MHAbce, 168 of 194 prevalent infections were genotyped. Of these, 90.5% were CRF01_AE, 2.4% were subtype B, and 7.2% showed discordant or dual probe reactivity, indicative of recombination or dual infection, respectively. Among 23 incident infections, 20 were sequenced. Eighteen CRF01_AE, one subtype B, and one CRF01/B recombinant strains were seen. Two CRF01/B and one CRF01/C recombinant were identified among selected prevalent infections. These results indicate that incident and prevalent HIV-1 infections in Rayong and Chon Buri during 1998-2001 were 90% CRF01_AE, 3% subtype B, and 7% either recombinant or dual. This study frames the genetic diversity of HIV-1 in these cohorts in their preparatory phase for the ongoing ALVAC-HIV (vCP1521) prime, AIDSVAX B/E boost, phase III vaccine trial and will provide a benchmark for interpretation and analysis. 801 
INTRODUCTION G
ENETIC SUBTYPES OF HIV-1 will play a role in the efficacy of candidate vaccines. The relationships of strains incorporated into vaccines to those circulating in the populations where they will be tested influence the planning and interpretation of vaccine trials. The HIV-1 epidemic in Thailand has long been attractive for vaccine trials because it is dominated by CRF01_AE, a recombinant between subtypes A and E, whose interpatient diversity has remained relatively low since its introduction in the late 1980s. 1, 2 Candidate vaccines evaluated in Thailand have included genes from CRF01_AE. [3] [4] [5] The molecular epidemiology of HIV-1 in Thailand has been more complex since the inception of the epidemic. Thailand experienced a parallel introduction of CRF01_AE into the heterosexual risk group and subtype B into injecting drug users (IDU), almost simultaneously in the late 1980s. 6, 7 Until the mid1990s, the two strains remained separated by risk groups, 8 but by 1995, the first dual infections with the two strains had been recognized. 9 Since then, studies of many different cohorts, conducted in Thailand and in neighboring countries in South and Southeast Asia, have documented that intersubtype recombinants between CRF01_AE and other strains, including subtype B and subtype C, have been generated. [10] [11] [12] In southern China, at least two different but related recombinants between subtypes B and C are circulating, 13 and recombinants including CRF01_AE, B, and C have been identified in countries bordering Thailand, including China's Yunan Province [14] [15] [16] and Myanmar. 17, 18 High risk groups, including commercial sex workers (CSW) and IDUs, can be susceptible to multiple HIV-1 infections, and may play a role in the generation of new intersubtype recombinant strains. [19] [20] [21] [22] The intermixing of CRF01_AE and subtype B among IDUs in Thailand began to be documented almost a decade ago, 23 and two significant observations have followed: an increasing fraction of recombinant strains among IDUs in northern Thailand, 11 and the identification of a circulating recombinant form, CRF15_01B, in individuals with both IDU and heterosexual exposure. 24 The bridge between IDU and heterosexual networks seems to have been crossed by at least one specific recombinant form of HIV-1, and the potential for the generation of new recombinant forms in Thailand has been well established.
Against this changing molecular picture, evaluation of HIV-1 genotypes in potential vaccine cohorts must include large sample sets, to identify recombinants among the majority CRF01_AE component, and should be proximal to the intended vaccine trial, both in time and with respect to the source population for volunteers. Here we report HIV-1 genotypes from 195 participants in cohort development studies in Rayong and Chon Buri Provinces in southeastern Thailand, where a Phase III vaccine trial, ALVAC-HIV (vCP1521) prime, AIDSVAX, B/E boost, is currently underway. 4, 25 Additional information about these cohorts has been reported. 26 
MATERIALS AND METHODS

Samples
Materials used for genotyping of HIV-1 strains included cryopreserved peripheral blood mononuclear cells (PBMC) or plasma from participants in one of two studies: RV121, which enrolled 1852 women, aged 20-45 years, attending family planning clinics in Rayong Province, Thailand between 1998 and 2001, or RV126, a community cohort consisting of 2500 volunteers, 52% of whom were women, in Chon Buri Province during the same interval. 26 Volunteers completed informed consent and both studies were conducted with approval from all relevant institutional review boards. HIV-1 infections in volunteers who were HIV-1 seropositive at the time of enrollment were considered to be prevalent infections. HIV-1 testing of initially seronegative volunteers at each prospective visit identified incident infections and allowed an estimation of the time since infection for the samples that were genotyped.
Multiregion hybridization assay for subtype B, C, and CRF01_AE (MHAbce)
RNA was extracted from 200 l of plasma using the NucliSens extraction kit (Organon Teknika Corp, Netherlands), and reverse transcription-polymerase chain reaction (RT-PCR) was performed using the QIAGEN OneStep RT-PCR kit (QI-AGEN, Valencia, CA). Reverse transcription and first round PCR were performed in one tube, which contained 2 l of extracted RNA, 600 nM outer primers, and other components as directed by the supplier, in an ABI9600 thermocycler (Applied Biosystems). The thermocycle routine was 1 cycle of 50°C, 30 min; 95°C, 15 min; 3 cycles of 95°C, 1 min, 55°C, 1 min, 72°C, 1 min; 27 cycles of 95°C, 10 sec, 55°C, 20 sec, 72°C, 1 min; finally 72°C for 10 min. The second round PCR contained 2 l of first round product, 480 nM primers, 250 M dNTPs, 3.5 mM MgCl 2 , 220 nM probe, 1.5U AmpliTaq Gold in 1ϫ Taqman Universal Master Mix (Applied Biosystems, Foster City, CA). Second round amplification was performed in a 96-well spectrofluorometric ABI7700 Sequence Detection System (Applied Biosystems) for 40 cycles of 95°C, 15 sec, 55°C, 1 min, 60°C, 1 min. Primers and subtype-specific probes used for this assay are described in Fig. 1 . Probes were labeled with 6-FAM. Fluorescence intensity was monitored at each cycle and samples were considered positive when fluorescence increased exponentially over at least five consecutive cycles. Negative control samples in each plate established fluorescence threshold for positivity, essentially as described. 27 Complete genome sequencing DNA was isolated from PBMC using the QIAmp blood extraction kit (QIAGEN, Inc.). A nested PCR strategy with near end-point dilution of DNA template in the first round PCR was employed to recover an amplicon encompassing almost the complete genome of HIV-1, from the end of the 5Ј LTR to the end of the U3 region of the 3Ј LTR. Primers used were MSF12b/OFMR1 for the first round and F2NST/OFM19 for the second round. Amplicons were purified using a microcon-100 column (Millipore Corp., Billerica, MA). The DNA template was directly sequenced on both strands using Big Dye terminator reaction kits and an ABI3100 capillary sequencer (Applied Biosystems, Foster City, CA). DNA sequences were assembled using Sequencher v3.1 (Genecodes Inc., Ann Arbor, MI).
Phylogenetic analysis
Newly derived sequences were aligned with reference sequences of all relevant HIV-1 subtypes and CRF. Phylogenetic analysis was performed using SEQBOOT, DNADIST (Kimura two-parameter, transition/transversion ratio ϭ 2.0), NEIGH-BOR, and CONSENSE modules of the PHYLIP package and trees were constructed with TREETOOL. Bootscanning was carried out with Maximum Parsimony using a sliding window of 300 nucleotides (nt) overlapping by 20 nt. The sequence was broken into segments from different subtypes and each segment was further analyzed for its subtype association with reference sequences of all relevant subtypes and CRF. Bootstrap values of 70% or greater were considered significant and permitted subtype assignment of the different segments. Sequences with multiple in-frame stop codons were investigated for hypermutation using HYPERMUT (http://hiv-web.lanl.gov) with strain C3198 used as a nonhypermutated reference sequence.
RESULTS
Study subjects and samples analyzed
In Rayong, 1852 female participants were recruited from public family planning clinics; in this group the HIV-1 prevalence was 3.9%. Their only reported risk factor for HIV-1 infection was heterosexual exposure. In Chon Buri, the study involved a community cohort of 2500 men and women, with an HIV-1 prevalence at baseline of 4.8%. In Chon Buri, 21% of prevalent cases reported both heterosexual and IDU risks. There were 73 prevalent and 6 incident infections identified among participants in the Rayong cohort. In Chon Buri, 121 prevalent and 17 incident infections were identified. Of these, 87% of the incident and 87% of the prevalent infections were characterized with respect to HIV-1 subtype by one or more approaches.
HIV-1 genotyping by MHAbce
Preliminary genotyping of samples from these cohorts using V3 peptide serotyping and partial sequencing of env or pol gene indicated that the majority strain was CRF01_AE, and a minority of samples was either subtype B or showed a discordant subtype in different genome regions (data not shown). Accordingly, a new approach to HIV-1 genotyping was developed that could provide the ability to distinguish subtypes from recombinant strains more efficiently.
A recently developed genotyping approach for HIV-1 subtypes A, C, and D using fluorescent, subtype-specific probes in multiple genome regions of HIV-1 27 has provided efficient and accurate surveillance of subtypes, recombinants, and dual infections in cohorts in East Africa, where these subtypes predominate. 28, 29 The principle of the MHAacd assay was adapted to address strains in Thailand and throughout Southeast Asia, namely CRF01_AE, and subtypes B and C. Using alignments of complete genome sequences from 13 CRF01_AE, 19 subtype B, and 6 subtype C strains, and five recombinants between CRF01_AE and B or C, four genome regions were identified where probes could be designed to distinguish CR01_AE, B, and C. Flanking regions were used to design PCR primers in regions with little or no sequence variation among all strains. The design of the assay and primers and probes used are shown in Fig. 1 . First-round PCRs were performed conventionally. Each first-round amplicon was distributed to second-round PCRs, and separately amplified in the presence of a subtypespecific probe in an ABI7700 Sequence Detection System. Accumulating fluorescence indicated which probe had hybridized or, in the case of coinfected individuals, which two subtypes were present. The assay utilized DNA extracted from primary PBMC or RNA extracted from plasma or serum, by incorporation of an RT step in the latter case. Thermocycle conditions and additional assay details are provided in Materials and Methods.
The performance of the MHAbce was initially evaluated on a panel of samples previously characterized by complete genome sequencing. Twenty-five samples were RNA extracted from plasma, representing 21 HIV-1 strains (CRF01_AE, subtype B, and subtype C infections) and 4 recombinants of these strains. Twenty-nine samples of DNA extracted from primary PBMC were also included; there were 23 strains (CRF01_AE, B, and C) and 6 recombinants. The sensitivity of the assay varied by genome region: 85.2% in gag, 90.7% in pol, 74.1% in vpr, and 81.5% in env. Loss in sensitivity resulted either from a failure to amplify a specific region or, after amplification, failure of any of the three probes to hybridize. The specificity of probe hybridization corresponded 100% to the subtype determined by sequencing.
Accordingly, prevalent infections from Rayong and Chon Buri cohorts were evaluated by the newly developed MHAbce, with the results shown in 
HIV-1 genotyping by complete genome sequencing
Complete genome sequencing provides a definitive characterization of HIV-1 genotypes, and was applied principally to the incident infections in Rayong and Chon Buri cohorts. In Rayong, 6 incident infections were identified, and all were se-WATANAVEERADEJ ET AL. 804 a Study participants were evaluated every 6 months for HIV-1 infection. I, incident infections observed among participants who were seronegative at the baseline visit; P, prevalent infections identified at the baseline visit; * indicates individuals with IDU as well as heterosexual risk.
b Seroconversion date was estimated at the midpoint of the interval between the last negative and first positive HIV-1 test and used to calculate the relationship of the sample draw date used for HIV-1 genotyping relative to the date of seroconversion.
c Genotype was determined by complete genome sequencing and phylogenetic analysis. d n.a., not available.
quenced. In Chon Buri, there were 17 incident infections, of which 14 were sequenced. Among these 20 incident infections, 70% were sequenced within 6 months of seroconversion (Table  2 ). In addition, some prevalent infections were further characterized by complete genome sequencing; these included one apparent subtype B infection from Chon Buri and 6 discordant or dual samples, 2 from Rayong and 4 from Chon Buri. Table 2 provides demographic and sampling data on the 27 samples that were sequenced. The phylogenetic relationships of the complete genome sequences are shown in Fig. 2 . The majority of sequences clustered with CRF01_AE, and specifically with reference strains from Thailand (CM240, TH253), rather than those from Africa (CF402, CF4071, CF1169). Four sequences represented intersubtype recombinants combining CRF01_AE with subtype B (R1741, C2254, R2399) or with subtype C (C2266). Two sequences were subtype B (C1416 and C3198), clustering specifically with the reference sequence for the BЈ variant common in Southern China and Thailand. Except for three CRF01_AE sequences that could not be considered because of hypermutation (Fig. 2, sequences marked "*") , the newly sequenced CRF01_AE were roughly equidistant from each other and sequences from the two cohorts were interspersed in the tree.
Overall, 6 of 6 incident infections from Rayong were CRF01_AE while, from Chon Buri, 12 were CRF01_AE, one was subtype B, and one was a recombinant between CRF01_AE and subtype B. As with the prevalent samples genotyped by MHAbce (Table 1) , about 10% of new infections in these provinces may be strains other than CRF01_AE.
Four of the complete genome sequences were recombinants between CRF01_AE and another subtype (Fig. 3 ). R1741 and R2399 were prevalent infections from Rayong selected for study because of preliminary evidence of a discordant genotype. R1741 was a recombinant between CRF01_AE and subtype B, with four crossover points along the genome. The strain was mostly CRF01_AE, except for a small region in pol and another segment encompassing the end of gp41 and the beginning of nef. No other recombinant of similar structure has yet been detected. Strain R2399 is one of four complete genomes of identical structure, now recognized, as CRF15_01B. 24 It is mostly CRF01_AE, with gp120 and the external portion of gp41 from subtype B. Strain C2254 was from an incident infection in Chon Buri in 1999. It is entirely CRF01_AE except for a segment in the mid-genome accessory region, which is subtype B. Finally, strain C2266, from a selected prevalent infection, combines CRF01_AE with subtype C, in a complex pattern with multiple crossovers across the genome. This strain has been fully described elsewhere 10 and, notably, represents the first reported incursion of subtype C genetic material into Thailand. Sequences from this study have been submitted to GenBank 
DISCUSSION
In 2003, a phase III prime-boost vaccine trial was initiated in Thailand, which is slated to screen 25,000 potential volunteers and enroll 16,000 into the study. This report frames the genetic diversity of HIV-1 in the communities from which these volunteers are being enrolled. Using a newly developed genetic screening assay, the MHAbce, on 168 samples, and by complete genome sequencing of 27 strains, a total of 195 samples were genotyped, representing 87% of all HIV-1-positive individuals identified in these preparatory cohort studies. Overall, 90% of prevalent infections and 90% of incident infections in these cohorts were CRF01_AE; 2.4% of prevalent and 5% of incident infections were subtype B, but the numbers are too small to determine whether this represents a significant difference. Of note, 8 prevalent and 1 incident infections, together representing 4.3% of all infections, were either recombinants between CRF01_AE and subtype B or C, or a dually infected individual who may be a source of such recombinants. This benchmark, based on viruses circulating in the period 1998-2001, will be useful when HIV-1 genotypes in these communities are evaluated in conjunction with the current phase III trial.
During this study, the rate of HIV-1 exposure related to injecting drug use was quite low, but it may be important that in two infected individuals in Chon Buri who did report such exposure, one HIV-1 strain was subtype B and the other was CRF01_AE (strains C1416 and C4382, Table 2 ). Intermixing of strains in a high-risk group may herald increasing dual infection and recombination in the future. It is also of interest that CRF15_01B, so far identified in multiple locations in Thailand and in individuals with IDU as well as heterosexual risk, has also been identified in these cohorts, namely strain R2399, a prevalent infection in Rayong.
The relationship of the HIV-1 genotypes identified here to the vaccines being used in the phase III prime-boost trial can be considered. The vaccine primes with ALVAC_HIV (vCP1521), a recombinant canarypox-vectored vaccine that expresses gag, protease, and the transmembrane anchor of gp41 from the subtype B strain LAI, and gp120 from CRF01_AE strain TH023. Boosting is with AIDSVAX˛ B/E, a bivalent HIV gp120 envelope glycoprotein vaccine from strains A244 and MN, representing CRF01_AE and subtype B, respectively. 4 At least 90% of the strains described here are CRF01_AE, subtype matched in gp120 to both the prime and the boost. The CRF15_01B strains, like R2399, match the boost in gp120 but not the prime. At least one strain with a subtype C envelope has been identified, which matches neither component of the vaccine. In gag/pol, the great majority of strains, almost all if this study is broadly representative, are subtype mismatched, because few of the recombinants seem to retain subtype B in the relevant region of gag and the pure subtype B stains represent less than 3% of the total. It will be important to keep these distinctions in mind as immune responses generated in vaccinees are evaluated.
Finally, the utility of MHAbce for HIV-1 genotyping in Thailand is evident. With the application of universal primers and subtype-specific probes in multiple genome regions, the high throughput of real-time PCR can be harnessed to distinguish subtypes and recombinant strains and to identify possible dual infections. This assay, part of a family of MHA for different regional epidemics including MHAacd for East Africa 27 and MHAcrf02 for West/West Central Africa, 30 is already in second generation development and application, with enhanced ability to monitor emerging recombinant forms throughout South and Southeast Asia (G . Kijak, et al., unpublished data) . The capacity to genotype all HIV-1-positive individuals during cohort development and in vaccine trials will provide a wealth of detailed information on factors that impact the spread of strains in populations and the relationships of breakthrough infections to strains circulating in vaccine cohorts. While the vast majority of prevalent infections could be genotyped from small serum samples, 13% could not be typed, probably due to a combination of factors including low viral load, poor sample preservation, unanticipated viral heterogeneity, and others. While not a replacement for the precision of complete genome sequencing, MHA assays have an important role to play because they maintain accuracy while expanding genotyping capacity many fold.
